Evaluation of whole-body MRI in diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors compared with the gold standard SSR-PET/CT

Evaluation of whole-body MRI in diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors compared with the gold standard SSR-PET/CT - NET_MET

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026239

Enrollment

Registered

2023-02-03

Start date

2021-12-06

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D48

Interventions

Group 1: A minimum of 20 to a maximum of 50 patients with NET eligible for study inclusion will be recruited for this study who are referred for MRI of the liver with liver-specific contrast agent and

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Clinically indicated MRI examination, Existing clinical indication for liver MRI, Patient's legal capacity, available written documentation of the informed consent interview and patient's consent to participate in the study, Additional SSTR- PET-CT at the same time points (maximum 3 months time difference).

Exclusion criteria

Exclusion criteria: Impaired renal function (GFR < 30 ml/min/1.73m²), Known intolerance of gadolinium-containing contrast agent, Clinically or hemodynamically unstable patients, Other contraindications to MRI examination (claustrophobia, pacemakers or other implants not compatible with 3T MRI, metal shards, etc.), Pregnant women and nursing mothers

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy of whole-body MRI compared with PET/CT.	—

Secondary

Measure	Time frame
Demographic data (age & sex) and histopathological data of primarius (proliferation index (ki-67) and grading (G1- G3).	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026